Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. This has shown to result in a long term local disease control rate and a high cancer specific survival. The current trial addresses the issue if progression free survival (PFS) in patients treated with radiotherapy can be predicted by a multi-variate model derived from a composite of bio-imaging and biomarkers
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
5
hypofractionated radiation therapy
University Hospital Ghent
Ghent, Belgium
development and validation of a multi-variate predictive model
To develop and validate a multi-variate predictive model based on bio-imaging and biomarkers for progression)free survival from 2 to 5 years.
Time frame: from 2 to 5 years
the clinical response and complication rate
Time frame: from 2 to 5 years
local, regional or distant failure
Time frame: from 2 to 5 years
progression free survival
Time frame: from 2 to 5 years
disease specific overall survival
Time frame: from 2 to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.